GSK, India's Biological E Form JV To Develop Pediatric Vaccines
This article was originally published in PharmAsia News
GlaxoSmithKline and India's Biological E have agreed to form a joint venture for research and development of a novel pediatric vaccine covering six infectious diseases common to developing nations.
You may also be interested in...
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Comments ahead of the vaccine advisory committee ranged from public health groups opposed to emergency use authorizations, to industry requests for guidance on EUA labeling materials.
"One of the issues that COVID-19 has brought out is, how safe is the production of animal-based food products?"